Pharmidex

The visit is an opportunity for Danish and Swedish life sciences companies to meet a group of highly competent UK services companies. Head of Business Development Gary Manchee says: "The Nordic region is interesting due its well-developed infrastructure of biotech / life science clusters, major Pharma investment and the importance / value of CNS R&D. During the visit we aim to show researchers involved in the development of CNS drugs that Pharmidex has specialist CNS services, ADMET/PK platform technologies and drug discovery knowledge that can rapidly and cost-effectively identify new drugs that have the greatest opportunity for clinical success.  Pharmidex also possess a drug delivery technology that allows small and large therapeutic agents to access the CNS”.